Trials / Withdrawn
WithdrawnNCT00354367
Evaluate Efficacy of Certolizumab in Crohn's Patients With Draining Fistulas
A Phase IIIB Multicenter, Open Label, Randomized Clinical Trial Evaluating Efficacy of Certolizumab Pegol, a PEGylated Fab Fragment of Humanized Antibody to Tumor Necrosis Factor (TNF) in Crohn's Disease Patients With Draining Fistulas.
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- UCB Pharma · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
To investigate the clinical efficacy of certolizumab pegol for fistula closure in Crohn's disease subjects with active draining fistulas.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Certolizumab pegol |
Timeline
- Start date
- 2007-01-01
- First posted
- 2006-07-20
- Last updated
- 2012-05-28
Source: ClinicalTrials.gov record NCT00354367. Inclusion in this directory is not an endorsement.